(Q49647333)

21 February 2018

title

Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease. (English)

1 reference

21 February 2018

non-alcoholic fatty liver

main subject

1 reference

metabolic dysfunction–associated steatotic liver disease

inferred from title

1 reference

1

Ian A Rowe

1 reference

21 February 2018

publication date

1 January 2018

1 reference

21 February 2018

The lancet. Gastroenterology & hepatology

published in

1 reference

21 February 2018

volume

3

1 reference

21 February 2018

issue

1

1 reference

21 February 2018

page(s)

66-72

1 reference

21 February 2018

The challenge of overdiagnosis begins with its definition

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Preventing overdiagnosis: how to stop harming the healthy

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Drivers of poor medical care

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Evidence for overuse of medical services around the world

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn't there)

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Extrahepatic complications of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Fatty liver is an independent predictor of early carotid atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Overdiagnosis in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Long-term follow-up of patients with NAFLD and elevated liver enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Antioxidant supplements to prevent mortality

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Is widespread screening for hepatitis C justified?

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Sick individuals and sick populations

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Systematic review with meta-analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930142-5

7 January 2021

10.1016/S2468-1253(17)30142-5

Identifiers

DOI

1 reference

21 February 2018

1 reference

21 February 2018